Andreia Biolo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6383711/publications.pdf

Version: 2024-02-01

67 papers	2,180 citations	236925 25 h-index	233421 45 g-index
69 all docs	69 docs citations	69 times ranked	3737 citing authors

#	Article	IF	Citations
1	Identification and Prognostic Significance of an Epithelial-Mesenchymal Transition Expression Profile in Human Bladder Tumors. Clinical Cancer Research, 2007, 13, 1685-1694.	7.0	183
2	Aggressive Fluid and Sodium Restriction in Acute Decompensated Heart Failure. JAMA Internal Medicine, 2013, 173, 1058.	5.1	143
3	Chagas Cardiomyopathyâ€"Where Do We Stand After a Hundred Years?. Progress in Cardiovascular Diseases, 2010, 52, 300-316.	3.1	123
4	Ventricular dysfunction and dilation in severe sepsis and septic shock: Relation to endothelial function and mortality. Journal of Critical Care, 2012, 27, 319.e9-319.e15.	2.2	123
5	Relationship of Plasma Galectinâ€3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure. Journal of the American Heart Association, 2012, 1, e000760.	3.7	105
6	EstatÃstica Cardiovascular â€“ Brasil 2020. Arquivos Brasileiros De Cardiologia, 2020, 115, 308-439.	0.8	96
7	Cardiac-Specific Overexpression of Catalase Identifies Hydrogen Peroxide-Dependent and -Independent Phases of Myocardial Remodeling and Prevents the Progression to Overt Heart Failure in Gî±q-Overexpressing Transgenic Mice. Circulation: Heart Failure, 2010, 3, 306-313.	3.9	66
8	Episodes of Acute Heart Failure Syndrome Are Associated With Increased Levels of Troponin and Extracellular Matrix Markers. Circulation: Heart Failure, 2010, 3, 44-50.	3.9	64
9	Impact of Î²1-Adrenergic Receptor Polymorphisms on Susceptibility to Heart Failure, Arrhythmogenesis, Prognosis, and Response to Beta-Blocker Therapy. American Journal of Cardiology, 2008, 102, 726-732.	1.6	62
10	Arterial Stiffness and Vascular Load in Heart Failure. Congestive Heart Failure, 2008, 14, 31-36.	2.0	60
11	Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis. Circulation: Heart Failure, 2008, 1, 249-257.	3.9	53
12	An Analysis of the Global Expression of MicroRNAs in an Experimental Model of Physiological Left Ventricular Hypertrophy. PLoS ONE, 2014, 9, e93271.	2.5	53
13	A Simple Clinically Based Predictive Rule for Heart Failure In-Hospital Mortality. Journal of Cardiac Failure, 2006, 12, 587-593.	1.7	51
14	Cytosolic H₂O₂ mediates hypertrophy, apoptosis, and decreased SERCA activity in mice with chronic hemodynamic overload. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H1453-H1463.	3.2	51
15	Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo -inositol trispyrophosphate. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1926-1929.	7.1	47
16	Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. European Heart Journal, 2019, 40, 3605-3612.	2.2	46
17	Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. Biomarkers, 2014, 19, 135-141.	1.9	43
18	Prognostic role of phase angle in hospitalized patients with acute decompensated heart failure. Clinical Nutrition, 2016, 35, 1530-1534.	5.0	41

#	Article	IF	Citations
19	Dynamic changes in bioelectrical impedance vector analysis and phase angle in acute decompensated heart failure. Nutrition, 2015, 31, 84-89.	2.4	38
20	Dynamics in Insulin Resistance and Plasma Levels of Adipokines in Patients With Acute Decompensated and Chronic Stable Heart Failure. Journal of Cardiac Failure, 2011, 17, 1004-1011.	1.7	37
21	Posicionamento sobre DiagnÃ³stico e Tratamento da Amiloidose CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 561-598.	0.8	35
22	A nurseâ€based strategy reduces heart failure morbidity in patients admitted for acute decompensated heart failure in Brazil: the <scp>HELENâ€Ⅱ</scp> clinical trial. European Journal of Heart Failure, 2014, 16, 1002-1008.	7.1	32
23	Increased Expression of Tumor Necrosis Factor-Î± in Diabetic Macrovasculopathy. Cardiovascular Pathology, 1999, 8, 145-151.	1.6	27
24	A systematic review of microRNAs in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2021, 327, 146-154.	1.7	26
25	Determinants of Adiponectin Levels in Patients With Chronic Systolic Heart Failure. American Journal of Cardiology, 2010, 105, 1147-1152.	1.6	25
26	Anemia in Heart Failure: Association of Hepcidin Levels to Iron Deficiency in Stable Outpatients. Acta Haematologica, 2013, 129, 55-61.	1.4	25
27	Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: Results from a randomized clinical trial. Nutrition, 2018, 54, 111-117.	2.4	24
28	Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure. Molecular Medicine Reports, 2018, 17, 4736-4746.	2.4	24
29	Circulating microRNAs in obese and lean heart failure patients: A caseâ€“control study with computational target prediction analysis. Gene, 2015, 574, 1-10.	2.2	21
30	Polymorphisms of Matrix Metalloproteinases in Systolic Heart Failure: Role on Disease Susceptibility, Phenotypic Characteristics, and Prognosis. Journal of Cardiac Failure, 2011, 17, 115-121.	1.7	19
31	A prospective, comparative study on the early effects of local and remote radiation therapy on carotid intimaâ€“media thickness and vascular cellular adhesion molecule-1 in patients with head and neck and prostate tumors. Radiotherapy and Oncology, 2011, 101, 449-453.	0.6	18
32	Usefulness of the Aldosterone Synthase Gene Polymorphism C-344-T to Predict Cardiac Remodeling in African-Americans Versus Nonâ€“African-Americans With Chronic Systolic Heart Failure. American Journal of Cardiology, 2007, 100, 285-290.	1.6	16
33	Yoga and breathing technique training in patients with heart failure and preserved ejection fraction: study protocol for a randomized clinical trial. Trials, 2018, 19, 405.	1.6	15
34	Polymorphisms of endothelial nitric oxide synthase gene in systolic heart failure: An haplotype analysis. Nitric Oxide - Biology and Chemistry, 2012, 26, 141-147.	2.7	14
35	Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival. PLoS ONE, 2016, 11, e0161666.	2.5	13
36	Cardiac hypertrophy in mice submitted to a swimming protocol: influence of training volume and intensity on myocardial renin-angiotensin system. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 316, R776-R782.	1.8	13

#	Article	IF	Citations
37	AtualizaÃ§Ã£o de TÃ³picos Emergentes da Diretriz Brasileira de InsuficiÃªncia CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 116, 1174-1212.	0.8	13
38	Association study of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene with susceptibility and prognosis of heart failure. Gene, 2012, 510, 7-13.	2.2	12
39	Use of ghrelin in cachexia syndrome: a systematic review of clinical trials. Nutrition Reviews, 2016, 74, 659-669.	5.8	12
40	Early use of cardiac troponin-I and echocardiography imaging for prediction of myocardial infarction size in Wistar rats. Life Sciences, 2013, 93, 139-144.	4.3	11
41	Improvement in Clinical Outcomes in Acute Coronary Syndromes After the Implementation of a Critical Pathway. Critical Pathways in Cardiology, 2003, 2, 222-230.	0.5	9
42	Serum procollagen type III is associated with elevated right-sided filling pressures in stable outpatients with congestive heart failure. Biomarkers, 2009, 14, 438-442.	1.9	9
43	SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. Arquivos Brasileiros De Cardiologia, 2017, 108, 290-296.	0.8	9
44	Systems biology approach identifies key regulators and the interplay between miRNAs and transcription factors for pathological cardiac hypertrophy. Gene, 2019, 698, 157-169.	2.2	9
45	Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial. American Heart Journal, 2017, 194, 125-131.	2.7	8
46	Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II. Heart, 2021, 107, 1487-1492.	2.9	8
47	Implications of the Hemodynamic Optimization Approach Guided by Right Heart Catheterization in Patients with Severe Heart Failure. Arquivos Brasileiros De Cardiologia, 2002, 78, 261-266.	0.8	7
48	QRS Widening Rates and Genetic Polymorphisms of Matrix Metalloproteinases in a Cohort of Patients With Chronic Heart Failure. Canadian Journal of Cardiology, 2014, 30, 345-351.	1.7	7
49	Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure. Scientific Reports, 2018, 8, 9446.	3.3	7
50	Effect of fluid and dietary sodium restriction in the management of patients with heart failure and preserved ejection fraction: study protocol for a randomized controlled trial. Trials, 2014, 15, 347.	1.6	5
51	Identification of Candidate Biomarkers for Transplant Rejection from Transcriptome Data: A Systematic Review. Molecular Diagnosis and Therapy, 2019, 23, 439-458.	3.8	5
52	Characterization of advanced glycation end products and their receptor (RAGE) in an animal model of myocardial infarction. PLoS ONE, 2019, 14, e0209964.	2.5	5
53	Manejo nÃ£o farmacolÃ³gico de pacientes com insuficiÃªncia cardÃaca descompensada: estudo multicÃªntrico - EMBRACE. ACTA Paulista De Enfermagem, 2012, 25, 660-665.	0.6	4
54	N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2015, 8, 328-337.	2.4	4

#	Article	IF	Citations
55	MIBG cardiac imaging compared to ejection fraction in evaluation of cardiotoxicity: a systematic review. Journal of Nuclear Cardiology, 2022, 29, 2274-2291.	2.1	3
56	Preditores clÃnicos de fraÃ§Ã£o de ejeÃ§Ã£o preservada em insuficiÃªncia cardÃaca descompensada. Arquivos Brasileiros De Cardiologia, 2010, 94, 385-393.	0.8	2
57	Mental health initiatives for medical students in Brazil. Lancet Psychiatry,the, 2019, 6, e26.	7.4	2
58	Adaptation and Applicability of a Diuretic Algorithm for Patients with Heart Failure. Arquivos Brasileiros De Cardiologia, 2013, 100, 553-60.	0.8	2
59	Effective Treatment Reduces Arterial Stiffness and Load in Decompensated Heart Failure. Journal of Cardiac Failure, 2006, 12, S17.	1.7	1
60	Cardiovascular Epidemiology: The Legacy of Sound National and International Studies. Arquivos Brasileiros De Cardiologia, 2013, 101, 98-100.	0.8	1
61	Effect of a diuretic adjustment algorithm and nonpharmacologic management in patients with heart failure: study protocol for a randomized controlled trial. Trials, 2015, 16, 44.	1.6	1
62	The tip of the iceberg in the sub-Saharan Africa: unraveling the real world in the diagnosis and treatment of heart failure. Heart, 2017, 103, 1842-1843.	2.9	1
63	Right ventricular function during trastuzumab therapy for breast cancer. International Journal of Cardiovascular Imaging, 2022, 38, 779-787.	1.5	1
64	Inotropic and Vasoactive Agents in the Cardiac Intensive Care Unit. , 2010, , 470-478.		0
65	Effects of a diuretic adjustment algorithm protocol on heart failure admissions: A randomized clinical trial. Journal of Telemedicine and Telecare, 2021, 27, 288-297.	2.7	0
66	The Burden of Heart Failure in Brazil: Are we Providing Better Care or Just more Expensive Care?. International Journal of Cardiovascular Sciences, 2019, , .	0.1	0
67	Heart Failure Due to Cardiac Transthyretin Amyloidosis. , 2021, 1, 161-166.		0